PMID: 11927294Apr 3, 2002Paper

Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy

Urology
Brent K HollenbeckM G Sanda

Abstract

Brachytherapy is increasingly used as a treatment for localized prostate cancer but information regarding long-term, postimplantation, patient-reported sexual health-related quality-of-life (HRQOL) is scant. Neoadjuvant hormonal therapy is commonly administered with brachytherapy, yet its potentially adverse effects on subsequent sexual health have not been described using a validated HRQOL instrument. We used a validated HRQOL survey to characterize the significance of neoadjuvant hormonal therapy and other baseline factors on postimplantation sexual function and impairment. A cross-sectional survey using the expanded prostate cancer index composite HRQOL instrument was administered to all 114 localized prostate cancer patients who underwent ultrasound-guided, transperineal brachytherapy during a 4-year period and to 142 age-matched control men. Multivariable models measured the association of baseline factors and covariates with postimplantation sexual HRQOL. Older age (P = 0.01) and neoadjuvant hormonal therapy (P = 0.009) were independently associated with diminished sexual HRQOL after prostate brachytherapy. Among patients younger than 69 years old, 33% reported at least fair sexual function after brachytherapy alone compa...Continue Reading

References

Mar 1, 1994·International Journal of Radiation Oncology, Biology, Physics·L KleinbergL Harrison
May 1, 1996·International Journal of Radiation Oncology, Biology, Physics·R G StockC Iannuzzi
Jul 20, 1999·The Journal of Urology·M J Barry
Feb 25, 2000·The Journal of Urology·J M BrandeisR E Reiter
Sep 26, 2000·International Journal of Impotence Research·R F Sánchez-OrtizS B Malkowicz
Aug 3, 2001·International Journal of Radiation Oncology, Biology, Physics·L PottersM W Kattan
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John T WeiMartin G Sanda

❮ Previous
Next ❯

Citations

Apr 2, 2003·Current Oncology Reports·Aaron E Katz, John C Rewcastle
May 21, 2003·Current Urology Reports·David F Penson, Mark S Litwin
May 24, 2005·Urologic Oncology·Marcus L Quek, David F Penson
Apr 30, 2003·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·György Kovács, Razvan Galalae
Jun 11, 2009·Journal of the National Cancer Institute·John L GoreMark S Litwin
Oct 9, 2007·The Cancer Journal·David F Penson
Dec 5, 2002·Pharmacoepidemiology and Drug Safety
Jul 26, 2014·The Journal of Sexual Medicine·Catherine BenedictFrank J Penedo
Feb 22, 2012·Urologic Oncology·Andreas StensvoldSigbjørn Smeland
Aug 21, 2010·The Journal of Urology·John L GoreMark S Litwin
Dec 17, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Michael PinkawaMichael J Eble
Jul 17, 2008·Supportive Cancer Therapy·Nikhil L Shah, Martin Sanda
Oct 1, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Deborah FitzsimmonsColin D Johnson
Feb 13, 2007·International Journal of Radiation Oncology, Biology, Physics·Catherine BuronAlain Livartowski
Aug 27, 2004·BJU International·Nicole L Miller, Dan Theodorescu
Jul 25, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Amy E HaskinsMoritz Hansen
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David C MillerJohn T Wei
Oct 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Frank J Penedo, Jason R Dahn
Jul 8, 2011·The Cochrane Database of Systematic Reviews·Frank PeinemannStefan Sauerland
Jun 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Sven D'haese, Andrew Bottomley
Sep 26, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Sharon Odeo, Amsalu Degu
Feb 20, 2020·Clinical and Translational Radiation Oncology·Julia MurrayUNKNOWN CHHiP Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.